The FDA approved the use of prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI.
| Quantity | 10mg, 5mg |
|---|
The FDA approved the use of prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI.
| Quantity | 10mg, 5mg |
|---|
Reviews
There are no reviews yet.